180 related articles for article (PubMed ID: 29122813)
1. American Heart Association Principles on the Accessibility and Affordability of Drugs and Biologics: A Presidential Advisory From the American Heart Association.
Antman EM; Creager MA; Houser SR; Warner JJ; Konig M;
Circulation; 2017 Dec; 136(24):e441-e447. PubMed ID: 29122813
[TBL] [Abstract][Full Text] [Related]
2. Prescription drug prices in the US.
Med Lett Drugs Ther; 2017 May; 59(1521):81-83. PubMed ID: 28520697
[No Abstract] [Full Text] [Related]
3. Comparing Onset of Biosimilar Versus Generic Competition in the United States.
Beall RF; Ronksley PE; Wick J; Darrow JJ; Sarpatwari A; Kesselheim AS
Clin Pharmacol Ther; 2020 Dec; 108(6):1308-1314. PubMed ID: 32621540
[TBL] [Abstract][Full Text] [Related]
4. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
Falit BP; Singh SC; Brennan TA
Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110
[TBL] [Abstract][Full Text] [Related]
5. Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA.
Bennett CL; Sartor OA; Armitage JO; Kantarjian H
Lancet Oncol; 2017 Jan; 18(1):22-23. PubMed ID: 28049571
[No Abstract] [Full Text] [Related]
6. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
Crespi-Lofton J; Skelton JB
J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
[TBL] [Abstract][Full Text] [Related]
7. A GUIDE TO FOLLOW-ON BIOLOGICS AND BIOSIMILARS WITH A FOCUS ON INSULIN.
Dolinar R; Lavernia F; Edelman S
Endocr Pract; 2018 Feb; 24(2):195-204. PubMed ID: 29466056
[TBL] [Abstract][Full Text] [Related]
8. The economic implications of biosimilars.
Singh SC; Bagnato KM
Am J Manag Care; 2015 Dec; 21(16 Suppl):s331-40. PubMed ID: 26788809
[TBL] [Abstract][Full Text] [Related]
9. Biosimilars and drug development in allergic and immunologic diseases.
Bonini S; Bonini M
J Allergy Clin Immunol; 2017 May; 139(5):1461-1464. PubMed ID: 28359671
[No Abstract] [Full Text] [Related]
10. Developing oncology biosimilars: an essential approach for the future.
Abraham J
Semin Oncol; 2013 Dec; 40 Suppl 1():S5-24. PubMed ID: 24267944
[TBL] [Abstract][Full Text] [Related]
11. Generics and Biosimilars: Barriers and Opportunities.
Scheckel CJ; Rajkumar SV
Mayo Clin Proc; 2021 Dec; 96(12):2947-2957. PubMed ID: 34728057
[No Abstract] [Full Text] [Related]
12. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
[TBL] [Abstract][Full Text] [Related]
13. Advancing Healthcare Reform: The American Heart Association's 2020 Statement of Principles for Adequate, Accessible, and Affordable Health Care: A Presidential Advisory From the American Heart Association.
Warner JJ; Benjamin IJ; Churchwell K; Firestone G; Gardner TJ; Johnson JC; Ng-Osorio J; Rodriguez CJ; Todman L; Yaffe K; Yancy CW; Harrington RA;
Circulation; 2020 Mar; 141(10):e601-e614. PubMed ID: 32008369
[TBL] [Abstract][Full Text] [Related]
14. [Can we transfer the mechanisms of the generics market to biosimilars?].
Jacke CO; Wild F
Versicherungsmedizin; 2016 Dec; 68(4):168-72. PubMed ID: 29144113
[TBL] [Abstract][Full Text] [Related]
15. Pharmaceuticals and Medical Devices: Cost Savings.
Steiner DJ;
Issue Brief Health Policy Track Serv; 2015 Dec; ():1-31. PubMed ID: 27116794
[No Abstract] [Full Text] [Related]
16. The role of generic medicines and biosimilars in oncology in low-income countries.
Renner L; Nkansah FA; Dodoo AN
Ann Oncol; 2013 Sep; 24 Suppl 5():v29-32. PubMed ID: 23975702
[TBL] [Abstract][Full Text] [Related]
17. Joint 24th Medicines for Europe and 21st International Generic and Biosimilars Association (IGBA) Annual Conference (June 13-15, 2018 - Budapest, Hungary).
Cross G
Drugs Today (Barc); 2018 Aug; 54(8):499-505. PubMed ID: 30209444
[TBL] [Abstract][Full Text] [Related]
18. Limited options to manage specialty drug spending.
Tu HT; Samuel DR
Res Brief; 2012 Apr; (22):1-13. PubMed ID: 23155549
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars in oncology: from development to clinical practice.
Rak Tkaczuk KH; Jacobs IA
Semin Oncol; 2014 Apr; 41 Suppl 3():S3-S12. PubMed ID: 24767633
[TBL] [Abstract][Full Text] [Related]
20. American Society of Clinical Oncology Position Statement on Addressing the Affordability of Cancer Drugs.
American Society of Clinical Oncology
J Oncol Pract; 2018 Mar; 14(3):187-192. PubMed ID: 29091534
[No Abstract] [Full Text] [Related]
[Next] [New Search]
